Verrill's patent attorneys specialize in assisting biotech and life science clients at every level from university research, to startups, to mid-market and large corporations. We understand the challenges of leveraging funding for product development from dynamic research programs in a competitive environment. We're experienced in US and foreign patent prosecution, patent litigation, post-grant proceedings, opinions related to non-infringement, invalidity, freedom to operate, inventorship disputes, licensing, portfolio analysis, and competitor analysis.

Our patent prosecutors have extensive experience dealing with patent eligibility matters and work with a wide array of technologies including the following:

  • Antibodies
  • Aptamers
  • Aquaculture
  • Biofuels
  • Cancer therapies and vaccines
  • CAR T-cells
  • Cell culture
  • Chromatography systems
  • CRISPR technology
  • Drug delivery vehicles
  • Drug formulation
  • ELISA
  • Fluorescence in situ hybridization
  • Food science and enzymes
  • Gene therapy
  • Genetic adjuvants
  • Genomics
  • Immunotherapeutics
  • Industrial chemical and biochemical processes
  • Medical diagnostics
  • Microscopy technology and image analysis
  • Modular agricultural systems
  • Nanoparticles
  • Nucleic acids
  • Nutritional biochemistry
  • Probes
  • Proteins
  • Sequencing technology
  • Small molecule pharmaceuticals
  • Spectrometry
  • Stem cells
  • Targeting of drugs and biologics
  • Test kits
  • Transgenic animals
  • Treatment of diabetes and metabolic diseases
  • Viral vectors

Examples of how our patent attorneys have helped their biotech clients include:

  • Quickly established a patent portfolio in the competitive CAR T-cell space to support funding efforts of a biotech startup.
  • Assisted an instrumentation company in an inventorship dispute with its research collaborator, resulting in the company establishing its own patent portfolio.
  • Obtained broad patent coverage for a biologics formulations company to support its partnering efforts.

Firm Highlights

Matter

Advised Fortune 500 Company on Group Health and Welfare Benefit Plans

We were engaged by a Fortune 500 manufacturing company to provide legal and compliance services regarding its group health and welfare benefit plans. During the course of our representation, we have advised the company...

News

Ruth Mattson quoted in Law360 article regarding new Massachusetts surtax

Event

Annual Update: Part 1 - 2022 Legal Year in Review (2nd Session)

Matter

Elections and Constitutional Law: Successfully Challenged Certification of Initiative Petition

In a victory for consumers and the ride-hailing public, the Massachusetts Supreme Judicial Court recently barred the Secretary of State from placing on the November ballot initiative petitions proposed by companies such as Uber...

Blog

IRS Guidance Expands Access to ACA Premium Tax Credit, Allows Cafeteria Plan Sponsors to Permit Employees to Revoke Family Coverage Mid-year

Final Regulations under Section 36B of the Internal Revenue Code On October 11, 2022, the Internal Revenue Service (IRS) issued Final Regulations under Code Section 36B relating to eligibility for the Affordable Care Act’s...

Blog

New IRS Determination Letter Program for 403(b) and 401(a) Plans

On November 7, 2022, the IRS issued Revenue Procedure 2022-40 , which allows certain tax-exempt employers (such as schools, charities, and churches) to apply for IRS determination letters on their individually designed section 403(b...

News

Verrill Welcomes Associates Brody Haverly-Johndro, Maye Emlein, Victoria Larson, Chris Petronio, Abby Plummer, and Alexander Read

Event

Annual Update: Part 1 - 2022 Legal Year in Review (1st Session)

Publication/Podcast

The PHE is Ending: Do You Know Where Your Waivers Are?

While the pandemic is not over, the COVID-19 public health emergency (PHE) is expected to expire soon, which means that a number of operational, safety, and billing standards that were waived at the beginning...

Publication/Podcast

Maine PUC Clarifies Ability of Level 2 Projects to “Leapfrog” Level 4 Projects in Interconnection Queue

After months of uncertainty over the issue of whether Level 2 renewable energy projects can “leapfrog” Level 4 projects in the queue, the Maine PUC clarified one of the ambiguities. Specifically, in response to...

Contact Verrill at (855) 307 0700